**Executive Summary**
The Ministry of Health and Family Welfare announced the exchange of a Memorandum of Understanding (MoU) between India's Central Drugs Standard Control Organisation (CDSCO) and the Brazilian Health Regulatory Agency (ANVISA) on February 21, 2026. The MoU aims to strengthen bilateral cooperation in the regulation of pharmaceutical and medical products and facilitate coordinated oversight. This collaboration is expected to enhance India-Brazil relations and improve public health outcomes.
**Key Points / Main Content**
* **Purpose and Scope**
* The MoU aims to strengthen bilateral cooperation in the regulation of pharmaceutical and medical products.
* It encompasses medical products, including pharmaceutical ingredients, drugs, biological products, and medical devices.
* **Objectives**
* Promote convergence in regulatory practices between India and Brazil.
* Enhance mutual understanding of regulatory systems.
* Facilitate effective and coordinated oversight of medical products.
* Strengthen supply chains, encourage regulatory best practices, and support access to affordable healthcare solutions.
* **Areas of Cooperation**
* Information sharing on pharmaceutical and medical product regulation.
* Regulatory capacity building.
* Cooperation in matters related to pharmaceutical and medical product regulation, in accordance with national laws and regulations.
* **Expected Outcomes**
* Ensuring the availability of safe, effective, and quality-assured medicines and medical products.
* Contributing to improved public health outcomes in both countries.
**Impact Analysis**
**CDSCO (India's Central Drugs Standard Control Organisation) and ANVISA (Brazilian Health Regulatory Agency)**
* **Impact:** Enhanced collaboration and harmonization of regulatory practices.
* **Action Required:** Engage in information sharing, regulatory capacity building, and coordinated oversight activities as outlined in the MoU.
**Healthcare Providers and Patients in India and Brazil**
* **Impact:** Increased availability of safe, effective, and quality-assured medicines and medical products.
* **Action Required:** Access healthcare solutions based on the collaborative efforts between India and Brazil.
**Pharmaceutical and Medical Device Manufacturers in India and Brazil**
* **Impact:** Potential for streamlined regulatory processes and enhanced market access in both countries.
* **Action Required:** Stay informed about the evolving regulatory landscape and leverage the benefits of the MoU for market expansion.
Key Entities Referenced
Memorandum of Understanding (MoU): Agreement between India and Brazil to strengthen bilateral cooperation in the field of regulation of pharmaceutical and medical products.
Central Drugs Standard Control Organisation (CDSCO): India's national regulatory authority for pharmaceuticals and medical devices. Signed the MoU on behalf of India.
Brazilian Health Regulatory Agency (ANVISA): Brazil's health regulatory agency. Signed the MoU on behalf of Brazil.
Ministry of Health and Family Welfare
India and Brazil Exchange MoU to Strengthen
Cooperation in Pharmaceutical and Medical
Products Regulation
Posted On: 21 FEB 2026 6:57PM by PIB Delhi
India and Brazil today exchanged a Memorandum of Understanding (MoU) to strengthen bilateral
cooperation in the field of regulation of pharmaceutical and medical products. The MoU was exchanged
between India’s Central Drugs Standard Control Organisation (CDSCO) and Brazilian Health Regulatory
Agency (ANVISA), marking an important step towards deeper regulatory collaboration between the two
countries. Director-President of ANVISA, Mr. Leandro Safatle and Indian Ambassador to Brazil, Shri
Dinesh Bhatia exchanged the MoU today in Hyderabad House in the august presence of Shri Narendra
Modi, Prime Minister of India and H.E. Luiz Inácio Lula da Silva, President of Brazil.
The MoU establishes a structured framework for cooperation and exchange of information in the field of
medical products, including pharmaceutical ingredients, drugs, biological products and medical devices. It
aims to promote convergence in regulatory practices, enhance mutual understanding of regulatory systems
and facilitate effective and coordinated oversight of medical products.
The exchange of the MoU reflects the shared commitment of India and Brazil to ensuring the availability
of safe, effective and quality-assured medicines and medical products for their populations. The agreement
is also expected to contribute to strengthening supply chains, encouraging regulatory best practices and
supporting access to affordable healthcare solutions.
The MoU between CDSCO and ANVISA builds upon the broader India–Brazil cooperation in the health
sector and complements existing institutional mechanisms for bilateral engagement. It underscores the
growing collaboration between the two countries in health, pharmaceuticals and medical technologies,particularly in the context of their shared priorities as leading Global South partners.
Through this MoU, both sides reaffirmed their intent to work closely in areas such as information sharing,
regulatory capacity building, and cooperation in matters related to pharmaceutical and medical product
regulation, in accordance with their respective national laws and regulations.
The exchange of the MoU is expected to further strengthen India–Brazil relations and open new avenues
for collaboration in the health and pharmaceutical sectors, contributing to improved public health
outcomes in both countries.
***
SR
HFW–India Brazil Health MoU/21st February 2026/2
(Release ID: 2231289) Visitor Counter : 246
Read this release in: Urdu , Marathi , ही , Telugu